IL-13 Blockade and Airway Autoimmunity in Asthma

Inclusion Criteria: * Prior to the beginning of the study, patients must be willing and fully capable to provide written informed consent * Subjects must be able and willing to comply with the study protocol * Asthma diagnosed by a respiratory physician ≥ 36 months prior to study enrollment based on the Global Initiative for Asthma (GINA) 2014 guidelines * Patients referred or routinely followed for asthma by Dr. Nair * Clinical indication to prescribe dupilumab or will enter a clinical trial where patient will receive drug for at least 4 months * ICS dose ≥ 500 mcg of fluticasone equivalent/day, and/or daily prednisone Exclusion Criteria: * Current smoker defined as having smoked at least one cigarette (or pipe, cigar, or marijuana) per day for ≥ 30 days within the three months prior to screening * Ex-smokers with ≥ 20 pack-year smoking history * Current pregnancy or lactation * Treatment with anti- Immunoglobulin E (IgE), anti-IL-5, or anti-IL-5 Receptor targeted therapy currently or within three months prior to Visit 1 * Any prior medical conditions or treatment history that the physician deems unfit (including but not restricted to chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis, pulmonary arterial hypertension, tuberculosis).